Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2023 | Cost-benefit considerations for TKI selection in CML

Hagop Kantarjian • 6 Sep 2023

SOHO 2023

Chronic Myeloid Leukemia Leukemia Bosutinib Dasatinib Imatinib Nilotinib Ponatinib

Hagop Kantarjian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses cost-benefit considerations when choosing a tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML). Many TKIs are becoming generic, and Prof. Kantarjian highlights the importance of considering the aims of the treatment to aid in TKI selection. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Ponatinib for CML and Ph+ ALL: five-year results from the PACE trial

Hagop Kantarjian • 6 Sep 2023

Unmet needs in CML: increasing treatment-free remission & accessibility to TKIs

Hagop Kantarjian • 6 Sep 2023

Venetoclax, CLAD/LDAC and azacitdine in older AML patients

Hagop Kantarjian • 30 Nov 2020

Ponatinib in chronic-phase CML patients with prior second generation TKI exposure

Hagop Kantarjian • 30 Nov 2020

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024